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Abstract
Background: Inhibins are important regulators of the female reproductive system. Recently, two new inhibin
subunits betaC and betaE have been described, although it is unclear if they are synthesized in normal human
endometrium.
Methods: Samples of human endometrium were obtained from 82 premenopausal, non-pregnant patients
undergoing gynecological surgery for benign diseases. Endometrium samples were classified according to
anamnestic and histological dating into proliferative (day 1-14, n = 46), early secretory (day 15-22, n = 18) and late
secretory phase (day 23-28, n = 18). Immunohistochemical analyses were performed with specific antibodies
against inhibin alpha (n = 81) as well as inhibin betaA (n = 82), betaB (n = 82), betaC (n = 74) and betaE (n = 76)
subunits. RT-PCR was performed for all inhibin subunits. Correlation was assessed with the Spearman factor to
assess the relationship of inhibin-subunits expression within the different endometrial samples.
Results: The novel inhibin betaC and betaE subunits were found in normal human endometrium by
immunohistochemical and molecular techniques. Inhibin alpha, betaA, betaB and betaE subunits showed a
circadian expression pattern, being more abundant during the late secretory phase than during the proliferative
phase. Additionally, a significant correlation between inhibin alpha and all inhibin beta subunits was observed.
Conclusions: The differential expression pattern of the betaC- and betaE-subunits in normal human endometrial
tissue suggests that they function in endometrial maturation and blastocyst implantation. However, the precise role
of these novel inhibin/activin subunits in human endometrium is unclear and warrants further investigation.
Background
Together with bone morphogenetic proteins (BMPs),
growth and differentiation factors (GDFs), myostatin,
Muellerian inhibiting substance (MIS) and other pro-
teins [1-3], inhibin and activin proteins belong to the
transforming growth factor-beta (TGF-b) family of
growth and differentiation factors. Within this inhibin
subgroup, one a-subunit and four b-subunit isoforms
(bA, bB, bC and bE) have been isolated in mammals
and humans [2-6]. The b-subunits can form activins by
dimerization with a second b-subunit, or alternatively,
they can form inhibins by dimerizing with an a-subunit.
Thus, depending on the subunit combination, there are
two isoforms of inhibin (inhibin A (a-bA) and inhibin B
(a-bB)) and three isoforms of activin (activin A (bA-
bA), activin B (bB-bB) and activin AB (bA-bB)) [2,3].
Recently, two additional b-subunits were identified in
humans, bC [4] and bE [6]. These two novel subunits
share 82% and 61% amino acid sequence similarity with
the corresponding mature proteins from rat and mouse,
respectively [7,8].
Inhibins and activins were initially isolated from the
gonads and have been demonstrated to be disulfide-
linked dimers [1-3]. Meanwhile, the well-studied inhibin
a-, bA-, and bB-subunits have been detected in normal
and abnormal endometrial tissue [9-15], and are impli-
cated as important paracrine modulators of reproductive
function [16,17] and malignant transformation
[12,13,18]. Moreover, inhibins and activins might play
an important role in endometrial cell function by
* Correspondence: ioannis.mylonas@med.uni-muenchen.de
1Ludwig-Maximilians-University Munich, 1st Department of Obstetrics and
Gynecology, Maistrasse 11, 80337 Munich, Germany
Full list of author information is available at the end of the article
Mylonas et al. Reproductive Biology and Endocrinology 2010, 8:143
http://www.rbej.com/content/8/1/143
© 2010 Mylonas et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.
regulating endometrial maturation, decidualization, and
human implantation processes [19-26].
However, only limited data on histological expression
of the inhibin/activin bC and bE subunits in normal
human endometrium are available. The inhibin bC pro-
tein was primarily expressed in human liver and prostate
[27], while inhibin/activin bE mRNA was predominantly
synthesized in human liver with low levels found in
heart, testis, leukocytes, and skeletal muscle [5]. Inhibin
bC was previously detected by immunohistochemical
methods in normal and abnormal placenta [28,29],
endometrial cell lines [30,31], endometrial cancer [32],
and cervical tissue [33]. Additionally, the inhibin bE is
synthesized in normal and abnormal placenta [5,34,35]
as well as human cervical tissue [36] and the endome-
trial cancer cell line Ishikawa [31].
Since specific monoclonal antibodies against inhibin
subunits are only recently available, systematic investiga-
tions on the combined expression of inhibin/activin sub-
units have not been performed. Uncovering the
differential expression patterns of the five inhibin/activin
subunits and their correlations in human endometrium
will further understanding of human reproduction. Addi-
tionally, knowledge of the expression patterns of the inhi-
bin b-subunits is important, since activin signaling might
be a promising target for therapeutic interventions [37].
Methods
Tissue samples
Immunohistochemical analysis of inhibin-subunits was
performed on a well-characterized patient group [11,38].
Samples of human endometrium were obtained from 82
premenopausal, non-pregnant patients undergoing gyne-
cological surgery for benign diseases (mainly uterine
leiomyoma) either by D&C (dilatation and curettage) or
hysterectomy. We had recently analyzed 54 endometrial
samples for the expression of inhibin-a, -bA and -bB
[11], that have been included in this study. All women
had a normal and regular menstrual cycle with no hor-
monal treatment for 3 months prior to surgery. All
pathological and hyperplastic endometrial samples were
excluded from this study. Endometrium samples were
classified according to anamnestic and histological dat-
ing into proliferative (day 1-14, n = 46), early secretory
(day 15-22, n = 18) and late secretory phase (day 23-28,
n = 18) as previously described [11,38-40].
Generation of a polyclonal inhibin-bE peptide antibody
Anti-inhibin bE polyclonal antibodies were generated as
custom-made antibodies in rabbits against a polypeptide
of 16 amino acids of inhibin bE (polypeptide-sequence:
NH2-CRWGPRRRRQGSRTLL-COOH; amino acid posi-
tion 144 to 158; accession number: AAH05161) as pre-
viously described by BioGenes (Berlin, Germany) [41].
This amino acid sequence is unique to the inhibin bE
subunit and is absent from other inhibin subunits. This,
as well as optimal immunogenic properties, was checked
prior to immunization by bioinformatic programs
(Antheprot; protein sequence alignments) [34].
A primary dose of 200 μg activin beta E polypeptide
was solubilized in Freund’s complete adjuvant (Sigma,
Aldrich, Germany) and injected subcutaneously into
rabbits. Three doses of the peptide solubilized in
Freund’s incomplete adjuvant were administrated at
6 week intervals. After the third booster injection
(14 days), blood was collected from the rabbit, and the
serum was separated. Antibodies were isolated by
column chromatography with a protein A column
(Amersham Pharmacia Biotech, Freiburg, Germany).
Immunohistochemistry
Immunohistochemical analyses were performed using a
combination of heat induced antigen retrieval and the
standard streptavidin-biotin-peroxidase complex using
the mouse (for the inhibin a, bA and bB antibodies),
goat (for inhibin bC antibody) or rabbit (for inhibin bE
antibody) IgG-Vectastain Elite ABC kit (Vector Labora-
tories, Burlingame, California, USA) as previously
described [11,31,34,36,41].
Antibodies used for these experiments are listed in
Table 1. The immunohistochemical procedures for inhi-
bin a-, bA- and bB-subunits were evaluated in normal
and malignant endometrial tissue [11-13,42,43], breast
cancer tissue [44], and uterine cervical cancer [45] as
well as normal and abnormal placenta [46,47]. The inhi-
bin bC antibody was previously evaluated in normal and
pathological placenta tissue [28,29], endometrial cell
lines [30,31], endometrial cancer [32] and cervical tissue
[33]. The immunohistochemical procedure for inhibin
bE was performed in ovarian tissue [41], endometrial
cancer cell lines [31], normal and abnormal placenta
[34], and uterine cervical tissue [36].
Briefly, paraffin-fixed tissue sections were dewaxed
using xylol for 15 min, rehydrated in descending series
of alcohol (100%, 96% and 70%), and subjected to anti-
gen retrieval for 10 min in a pressure cooker using
sodium citrate buffer (pH 6.0), containing 0.1 M citric
acid and 0.1 M sodium citrate in distillated water. After
reaching room temperature, sections were washed twice
in phosphate-buffered saline (PBS). Endogenous peroxi-
dase activity was quenched by immersion in 3% hydro-
gen peroxide (Merck, Darmstadt, Germany) in methanol
for 20 min. Non-specific binding of the primary antibo-
dies was blocked by incubating the sections with diluted
normal serum (10 ml PBS containing 150 μl horse
serum; provided by Vector Laboratories) for 20 min at
room temp. Sections were then incubated at room tem-
perature for 60 min with the primary antibodies for
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inhibin-a, -bA and -bB. Inhibin-a, -bA and -bB were
diluted in PBS. For inhibin-bC and -bE antibodies, sec-
tions were incubated at 4C over night with the inhibin-
bC polyclonal goat antibody at a dilution of 1:50 in
Ultra-V-Block (Lab Vision, Fremont, U.S.A.) or the inhi-
bin-bE polyclonal rabbit antibody at a dilution of 1:4000
in Ultra-V-Block (Lab Vision, Fremont, U.S.A.). After
washing with PBS, sections were incubated in diluted
biotinylated serum (10 ml PBS containing 50 μl horse
serum; provided by Vector Laboratories) for 30 min at
room temperature. After incubation with the avidin-bio-
tin peroxidase complex (diluted in 10 ml PBS; Vector
Laboratories) for 30 min and repeated washing steps
with PBS, visualization was performed with substrate
and chromogen 3,3’-diaminobenzidine (DAB; Dako,
Glostrup, Denmark) for 8-10 min. Sections were coun-
terstained with Mayer’s acidic hematoxylin and dehy-
drated in an ascending series of alcohol (50-98%). After
xylol treatment, sections were covered. Negative con-
trols were performed by replacing the primary antibody
with normal mouse, rabbit or goat IgG as isotype con-
trol in the same dilution compared to the primary anti-
body, respectively. Immunohistochemical staining was
performed using an appropriate positive control com-
prising ovaries containing follicular cysts [11,31,41].
Positive cells showed a brownish color and negative
controls as well as unstained cells were blue. Sections
were examined using a Leitz (Wetzlar, Germany) photo-
microscope. Digital images were obtained with a digital
camera system (JVC, Japan) and were saved on compu-
ter (Diskus software, Hilgers, Königswinter, Germany).
RT-PCR analysis
To analyze inhibin subunit expression at the transcrip-
tional level, RNA was extracted from samples of human
endometrium tissue of proliferative (n = 3) and secre-
tory phase (n = 3) cells, transcribed into cDNA, and
analyzed by RT-PCR analysis for the expression of inhi-
bin subunits a, bA, bB, bC and bE using specific pri-
mers (Table 2).
RNA was extracted from cells using the Nucleospin
RNA II kit (Macherey-Nagel, Düren, Germany) as pre-
viously described [29,31,34,36]. Reverse transcription
was performed with M-MLV reverse transcriptase and
oligo-dT (Promega, Mannheim, Germany) as recom-
mended by the supplier. PCR was performed in an
Eppendorf Mastercycler with GoTaq (Promega, Man-
nheim, Germany). Primer sequences are listed in Table
2. PCR cycling was performed after a 5 min initiation at
94°C with 36 cycles of 1 min at 94°C, 1 min at 57°C, 2
min at 72°C, followed by a 5 min extension at 72°C. For
a cDNA quality control, actin primers (Stratagene, The
Netherlands), amplifying a 661 bp product, were used.
As a further control, cDNA was omitted (water control)
to present any PCR contaminations [29]. PCR products
were separated on a 1.5% agarose gel, including a
pBR328 marker (Roth, Karlsruhe, Germany). Gels were
stained with SYBR Safe (1:10,000 dilution; Invitrogen,
Karlsruhe, Germany) prior to gel electrophoresis and
after a completed run transferred on a UV-permeable
tray to a BioRad Image Analyser (BioRad, Munich, Ger-
many) [29]. The generated electronic picture file was
exported as a TIFF file and imported in a Power-Point
presentation file in order to crop and label the figure.
Evaluation and statistical analysis
The intensity and distribution patterns of specific inhi-
bin-a, -bA,- bB, -bC and -bE subunit immunohisto-
chemical staining was evaluated using the semi-
quantitative score (IRS) as previously described and
Table 1 Antibodies used for immunohistochemical characterization of human endometrium
Antibody Clone Isotype Dilution Dilution medium Source
Inhibin-a R1 Mouse IgG2a 1:50 PBS Serotec, Oxford, UK
Inhibin-bA E4 Mouse IgG2b 1:50 PBS Serotec, Oxford, UK
Inhibin-bB C5 Mouse IgG2a 1:10 PBS Serotec, Oxford, UK
Inhibin-bC Polyclonal Goat IgG 1:50 Ultra-V-Block R&D Systems, Wiesbaden, Germany
Inhibin-bE Polyclonal Rabbit IgG 1:4000 Ultra-V-Block BioGenes, Berlin, Germany
Table 2 Primer sequences and length of amplification products
Forward primer (5’ – 3’) Backward primer (3’ – 5’) Length
Inhibin-a CCGGCCATCCCAGCATACACGC GAGTTGAGCGTCGGGCTCTC 359 bp
Inhibin-bA TGCCCTTGCTTTGGCTGAGA ACTTTGCCCACATGAAGCTTT 282 bp
Inhibin-bB GGCGAGCGGCGACTCAACCTAGA CGTGTGGAAGGAGGAGGCAGAGC 333 bp
Inhibin-bC GCAGCCCGGGTGAGAGTTGG ACTGCACCCACAGGCCTC 393 bp
Inhibin-bE AGCCCTTCCTAGAGCTTAAG GCTGCAGCCACAGGCC 404 bp
bp = base pairs
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used to asses inhibin/activin subunits [11,13]. Briefly, the
IRS score was calculated by multiplication of optical
staining intensity (graded as 0 = no, 1 = weak, 2 = mod-
erate and 3 = strong staining) by the percentage of posi-
tive stained cells (0 = no staining, 1 = <10% of the cells,
2 = 11-50% of the cells, 3 = 51-80% of the cells and 4 =
>81% of the cells). The slides were examined by two
independent observers, including a gynecological pathol-
ogist (N.S.). Sections were examined using a Leitz
(Wetzlar, Germany) photomicroscope. Digital images
were obtained with a digital camera system (JVC, Yoko-
hama, Japan) and were saved on computer (Diskus soft-
ware, Hilgers, Königswinter, Germany). The results were
evaluated using the non-parametric Mann-Whitney U
rank-sum test (SPSS, Version 17.0, Chigaco, IL, USA).
Correlation was assessed with the Spearman factor to
assess the relationship of inhibin-subunits expression
within the different endometrial samples. Significance
was assumed at p < 0.05 by using the two-tailed test.
Results
Immunohistochemical expression of inhibin-a, -bA, -bB,
-bC and -bE
To test the antibodies against the bC- and bE-subunits,
evaluation of the immunohistochemical staining reaction
was performed using appropriate positive controls,
including normal liver specimens (Figure 1a-b) and pre-
vious results were confirmed [5,29,31,34,36,41,48]. The
inhibin/activin a-, bA-, and bB-subunits were detected
in normal human endometrial tissue throughout the
menstrual cycle in accord with previous results (data
not shown). Inhibin a, bA, and bB were primarily
observed in glandular and luminal epithelial cells, with a
different staining intensity in stromal cells, especially
during secretory phase. Proliferative and secretory endo-
metria expressed the bA- and bB-subunits with a similar
pattern with the maximal immunostaining intensity
observed in secretory phase tissues (data not shown)
(Table 3) [11,15].
The bC-subunit was also detected in endometrial
glandular epithelial cells. A diffuse immunohistochem-
ical staining reaction was observed in cells representing
all stages of the menstrual cycle. The staining intensity
of cells was weaker during early secretory phase (Figure
2b) compared to the cells from endometrial samples
from proliferative phase (Figure 2a), while the maximal
immunostaining reaction was observed in cells isolated
from late secretory phase tissues (Figure 2c). Interest-
ingly, the bC-subunit immunoreactivity was detected in
all stages of the menstrual cycle examined with little
variation in intensity. (Figure 2c).
The inhibin bE-subunit was also expressed in human
endometrium primarily in the glandular and surface
epithelium. During proliferative phase, minimal
immunoreactivity was observed at the apical component
of glandular cells (Figure 3a). The staining intensity
increased in tissues from the early secretory phase, and
was localized to the basal and apical components of the
cells (Figure 3b). The strongest immunoreactivity was
observed during late secretory phase (Figure 3c). With
the onset of early secretory phase, the bE-subunit was
also detected in stromal cells (Table 3) (Figure 3c).
However, no statistically significant differences in immu-
noreactivity found in stromal cells was observed for
inhibin bC and bE at any stage of the menstrual cycle
(data not shown).
RT-PCR analysis
Figure 4 demonstrates that the mRNA of all inhibin
subunits is expressed in normal human endometrium
tissue of the secretory phase (Figure 4a) as well as of the
proliferative phase (Figure 4b). Overall, the expression of
inhibin subunit mRNAs appeared to be higher in the
Figure 1 Immunohistochemical expression of inhibin-bC and
-bE in normal liver tissue. Inhibin-bC (Figure 1a; magnification
×400) and bE (Figure 1b; magnification ×400) subunit demonstrated
a positive staining reaction in normal human liver tissue.
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secretory phase than in the proliferative phase, although
the small sample number and activities of potential reg-
ulatory mechanisms at the post-transcriptional level did
not allow further conclusions to be drawn.
Statistical analysis
A statistically significant correlation between the immu-
noreactive score (IRS) of the inhibin a and all inhibin b
subunits was observed by using the non-parametric
Spearmen correlation factor (p < 0.05). However, no sig-
nificant correlation between the amount of the bC-sub-
unit and the amount of the other b-subunits was
demonstrated. The IRS of the inhibin bE-subunit
showed a significant association with the amount of the
inhibin bB-subunit (p < 0.05) (Table 4).
The immunoreactive score for inhibin bA, bB and bE
increased between proliferative and late secretory phase
(p < 0.05) as well as between early and late secretory
phase (p < 0.05) (Figure 5). Inhibin a expression was
higher during late secretory phase compared to prolif-
erative endometrial tissue (p < 0.05), while the immu-
noreactive score for inhibin bC did not demonstrate any
changes during the menstrual cycle (Figure 5).
Discussion
Inhibin-subunits in human endometrium
Inhibins and activins were initially characterized as
endocrine and paracrine hormonal regulators of the
hypothalamic-pituitary-gonadal axis. Several autocrine
and paracrine actions of inhibins/activins have been
reported including modulation of ovarian and placental
hormone secretion [17,21,49,50], decidualization
[21-24,51], and trophoblast differentiation [20,52], as
well as effects on immunomodulatory function [53],
stem cell biology [54,55], and apoptosis [56]. However,
these putative functions have been characterized for
inhibin a, bA and bB isoforms, and it is not clear if the
bC- and bE- isoforms have similar function.
Meanwhile, these proteins are expressed in a wide
range of female reproductive tissues including normal
and abnormal human endometrium [9,10,12,13,15,42,43].
In this study, a circadian expression of the well-known
inhibin a-, bA-, and bB-subunits in normal human endo-
metrial tissue was demonstrated, confirming previous
results [10,11]. Moreover, expression of the novel inhi-
bin/activin bC- and bE-subunits was also demonstrated
in normal human endometrium by using RT-PCR and
immunohistochemical detection methods. The bE-subu-
nit demonstrated an increase in staining intensity
between proliferative and late secretory phase similar to
results with inhibin a, bA and bB immunolabeling. By
contrast, the bC-subunit did not show any difference in
immunohistochemical staining intensity between prolif-
erative and secretory phase. A decrease of the inhibin
bC-subunit staining intensity was demonstrated between
proliferative and late secretory phase, but this was not
statistically significant.
The inhibins a, bA and bB probably have important
functions in blastocyst implantation and contribute to
the paracrine signaling needed for adequate endometrial
maturation [22]. The potential roles of the novel inhi-
bin/activin subunits in human reproduction are intri-
guing. Results suggest that both bC- and bE-subunits
also play an important role in the human menstrual
cycle. Additionally, the distinct expression of inhibin-a
in the apical part of the glandular epithelial cells shows
the preferred synthesis of inhibins in the uterine lumen.
Since expression is lower in the endometrial stroma,
activins are probably produced and secreted into this
compartment [11].
Inhibin bC-subunit
Inhibin bC was primarily detected in hepatocytes [5,48]
and is implicated in the regulation of liver cell growth
as demonstrated by downregulation of inhibin bC
mRNA after partial hepatectomy in rats [57,58].
Table 3 Immunohistochemical findings determining localization and intensity of immunostaining intensity for
inhibin-a, -bA,- bB, -bC and -bE subunits in human endometrium across the normal menstrual cycle
Inhibin subunits Proliferative phase Early secretory phase Late secretory phase
Glandular epithelium a ± + ++
bA + + ++
bB + + ++
bC + + +
bE + + ++
Stromal cells a - + ++
bA - + ++
bB - + ++
bC + + +
bE - + ++
- = no staining; +/- = minimal staining + = positive staining; ++ = intense staining.
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Figure 2 Immunohistochemical expression of inhibin-bC in
normal human endometrial tissue. Immunohistochemical staining
reaction for inhibin-bC could be observed across the menstrual
cycle. Proliferative (Figure 2a, magnification ×250) and early
secretory endometria (Figure 2b, magnification ×125) expressed this
subunit, but with a weak intensity. The strongest staining intensity
could be observed during tissue samples late secretory phase
(Figure 2c, magnification ×400). Stromal cells also reacted positively
throughout the menstrual cycle.
Figure 3 Immunohistochemical expression of inhibin-bE in
normal human endometrial tissue. Immunohistochemical staining
reaction for inhibin-bE could be observed across the menstrual
cycle. Proliferative endometrial tissue (Figure 3a, magnification ×250)
demonstrated a weak staining intensity, while this intensity
increased during early (Figure 3b, magnification ×125) and late
secretory endometria. The strongest staining intensity could be
observed during tissue samples late secretory phase (Figure 3c,
magnification ×400). Stromal cells also reacted positively with a
minimal staining intensity in the proliferative phase, being moist
prominent during late secretory phase.
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The formation of homodimeric activin C (bC-bC), het-
erodimeric activins AC (bA-bC), BC (bB-bC), CE (bC-
bE), and inhibin C (a-b) has been demonstrated by
ectopic expression of the respective subunits in different
cell models [27,59]. Although the precise role of the bC
subunit has not been elucidated, several possible func-
tions have been suggested. Interestingly, ectopic expres-
sion of inhibin/activin bC subunit induced apoptosis in
human (HepG2, Hep3B) and rat (H4, EC3) hepatoma
cells [60,61]. In an immortalized mouse hepatocyte cell
line (AML12) and primary rat hepatocytes, activin bC
increased the rate of DNA synthesis [62]. Moreover, the
bC-subunit was identified as an autocrine growth modu-
lator in liver regeneration, leading to mitosis in a subset
of hepatocytes [63].
In human reproduction, this bC subunit is not
believed to be a significant regulator of activin bioactiv-
ity, since no abnormalities or malformations have been
observed in inhibin-bC knockout mice [48]. However,
there might be functional redundancy with other TGF-b
factors [64] and an antagonistic and regulatory role for
activin A bioactivity has recently been proposed
[27,64,65]. Interestingly, activin C (bC-bC) did not acti-
vate activin A (bA-bA) responsive promoters, and it was
suggested that the bC-subunit regulates the levels of
bioactive activin A (bA-bA) through the formation of
signaling incompetent activin AC heterodimers [64-66].
A preliminary study using RT-PCR and immunohisto-
chemical detection methods demonstrated expression of
inhibin bC in normal human endometrium and the
human endometrial carcinoma cell line Ishikawa [31].
The lower expression observed during early secretory
phase compared to that found in the proliferative phase
might suggest a mitotic function [63]. Thus, inhibin bC
might participate in the proliferation of human endome-
trium during the first phase of the menstrual cycle and
reduce the mitotic effect during blastocyst implantation.
However, no significant differences in bC-subunit
expression during the menstrual cycle were found. This
might be attributed either to the antibody used or to the
small number of samples analyzed. In addition, the
expression pattern of this subunit is different from the
other b-subunits, and this suggests that it may have a
different function in human endometrium.
Inhibin bE-subunit
Similar to the bC-subunit, the bE-subunit is predomi-
nantly expressed in hepatocytes, although it is also
detected in human heart, testis, peripheral blood
Figure 4 Inhibin/activin-subunit mRNA detection in normal
human endometrium tissue. The mRNA of all inhibin/activin-
subunits was detected in normal proliferative (Figure 4a) and
secretory (Figure 4b) human endometrium using PCR.
Table 4 Correlation between all five inhibin-subunits
Inhibin-a inhibin-bA inhibin-bB Inhibin-bC Inhibin-bE
Inhibin-a Correlation Coefficient (r) 0,409 0,534 0,260 0,533
p < 0,001 < 0,001 < 0,05 < 0,001
n 81 80 73 75
inhibin-bA Correlation Coefficient (r) 0,409 0,539 0,097 0,209
p < 0,001 < 0,001 N.S. N.S.
n 81 81 74 76
inhibin-bB Correlation Coefficient (r) 0,534 0,539 0,231 0,321
p < 0,001 < 0,001 = 0,05 < 0,01
n 80 81 73 75
Inhibin-bC Correlation Coefficient (r) 0,260 0,097 0,231 0,027
p < 0,05 N.S. = 0,05 N.S.
n 73 74 73 74 69
Inhibin-bE Correlation Coefficient (r) 0,533 0,209 0,321 0,027
p < 0,001 < 0,05 < 0,01 N.S.
n 75 76 75 69
N.S. = not significant
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leucocytes, and skeletal muscle tissue [5,6,61,67]. More-
over, inhibin bE is synthesized in normal and abnormal
placenta [5,34,35] and human cervix [36]. This novel
subunit was also demonstrated in the Ishikawa endome-
trial carcinoma cell line, which suggests that these cells
may be useful as an in vitro model for studying the bE-
subunit [31].
Formation of homodimeric activin E as well as hetero-
dimeric activins AE (bA-bE) and CE (bC-bE) has been
demonstrated after ectopic co-expression of these
respective subunits [5,8]. Interestingly, inhibin/activin
bE mRNA expression was transiently upregulated after
partial hepatectomy or portal vein branch ligation
[48,68]. When ectopically expressed in HepG2 or Hep3B
hepatoma cells or in the murine hepatocyte cell line
AML12, activin bE reduced the cell number and
increased apoptosis rates [61,62]. Moreover, transient
overexpression of bE by non-viral gene transfer in
mouse liver inhibited regenerative DNA synthesis [60].
These observations suggest that activin E may have a
growth limiting function similar to activin A [69]. How-
ever, the apoptotic function of the bE subunit in human
endometrial tissue remains unclear. The observed
increase in immunohistochemical staining of this subu-
nit during late secretory phase is similar to the increase
found for the bA-and bB-subunits [11] and suggests
they all could have a similar function. However, the
functions of these novel subunits and the formation of
putative inhibins and/or activins warrants further
research.
Conclusions
In conclusion, the inhibin bC- and bE-subunits were
expressed by normal human endometrial tissue. The
immunolabeling of inhibin bE in human endometrium
varied with the different stages of the menstrual cycle
while the synthesis of the bC-subunit did not. Although
the results show that epithelial cells are the predominant
source of these subunits in normal endometrium, they
were also detected in endometrial stroma throughout
the menstrual cycle. The differential expression pattern
of these b-subunits suggests that they have an important
function in endometrial maturation and blastocyst
implantation. Moreover, they probably participate in the
paracrine signaling necessary for adequate endometrial
maturation.
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